Evidence map›Paper›PMID 35155185›Full record

SynthesisFrontiers in oncology2021

Systematic Review With Meta-Analysis: Diagnostic, Prognostic and Clinicopathological Significance of CircRNA Expression in Renal Cancer.

Wujun Wang, Shengfang Xie, Dongping Yuan, Dandan He, Liming Fang, Fengfeng Ge

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Diagnostic value of circular RNAs as promising hematological biomarkers in acute myeloid leukemia: A systematic review and meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025
    Review
  4. Diagnostic Roles of circXPNPEP3 as Biomarker for Diabetic Nephropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wujun WangJiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Shengfang XieJiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Dongping YuanNanjing University of Chinese Medicine, Nanjing, China.
Dandan HeJiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Liming FangJiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Fengfeng GeJiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Jiangsu Province Hospital · CNNanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal cancer (RC) is one of the most common malignant tumors of the urinary system, and molecular targets for the specific diagnosis and treatment of RC have been widely explored. The purpose of this study was to systematically analyze circular RNAs (circRNAs), which may serve as novel tumor markers in terms of the diagnosis, prognosis and clinicopathological characteristics of RC.

methodsPubMed and Web of Science were systematically searched for literature as up to July 30, 2021. All included studies were evaluated by the evaluation system, and the results were satisfactory. Hazard ratios (HRs) and odds ratios (ORs) were used to assess the association of circRNAs with diagnostic and clinicopathological indicators. The sensitivity (SEN), specificity (SPE), positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the summary receiver operating characteristic curve (AUC) were combined to evaluate the diagnostic performance of circRNAs in RC.

resultsWe included 22 studies that met the criteria, including 18 that were prognostic, 4 that were diagnostic, and 12 that were clinicopathologically relevant. In terms of prognosis, we found that upregulated circRNAs were positively associated with poor overall survival in patients with RC (HR=1.63, 95% CI=1.43-1.85). In terms of diagnosis, the combined SEN, SPE and AUC of circRNAs in the diagnosis of RC were 0.82, 0.84 and 0.89 (0.86-0.91), respectively. In terms of clinicopathological features, upregulated circRNAs were associated with the Fuhrman grade (OR=0.641, 95% CI=0.471-0.873), T stage (OR=0.236, 95% CI=0.141-0.396), TNM stage (OR=0.225, 95% CI=0.158-0.321) and lymphatic metastasis (OR=0.329, 95% CI=0.193-0.560).

conclusionOur meta-analysis confirms that circRNAs may be candidate biomarkers for the diagnosis, prognosis, and clinicopathological indicators of RC.

Indexed as

circRNAclinicopathologicaldiagnosticmeta-analysisprognosticrenal cancer

Identifiers

PMID35155185
PMCPMC8832283
OpenAlexW4210624716

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.